


PATENT
ATTORNEY DOCKET NO. 50026/062001Certificate of Mailing: Date of Deposit: March 9, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Megan Kiley

Printed name of person mailing correspondence



Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Sueishi et al.	Confirmation No.:	2391
Serial No.:	10/598,947	Art Unit:	1614
Filed:	September 15, 2006	Examiner:	Not Yet Assigned
Customer No.:	21559		
Title:	METHODS FOR SUPRESSING TUMOR PROLIFERATION		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Applicants note that WO 97/16539 A1, WO 00/70055 A1, WO 00/70070 A1, WO 03/025570 A1, WO 03/029475 A1, WO 03/093476 A1, WO 03/102183 A1 and Shikada et al. ("A Role of Platelet-Derived Growth Factor –A (PDGF-A) in Non-Small Cell Lung Cancers and a Possibility of Platelet-Derived Growth Factor-A (PDGF-A) for Therapeutic

Target Molecule," *J. Jpn. Surg. Soc.* 105: 284 (#SF-081-1) (2004)) are written in the Japanese language, except for the English language abstract. English language translations of these publications are enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 9 March 2007



James D. DeCamp, Ph.D.
Reg. No. 43,580

JAN N. TITTEL, Ph.D.
Reg. No. 52,290

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/062001
	Serial No.	10/598,947
	Applicant	Sueishi et al.
	Filing Date	September 15, 2006
	Group	1614
	IDS Filed	March 9, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	US 2002/0169306 A1	Nov. 14, 2002	Kitazato et al.
	US 2003/0022376 A1	Jan. 30, 2003	Kitazato et al.
	US 2003/0166252 A1	Sep. 4, 2003	Kitazato et al.
	US 2003/0170266 A1	Sep. 11, 2003	Kitazato et al.
	US 2005/0191617 A1	Sep. 1, 2005	Inoue et al.
	US 2005/0221292 A1	Oct. 6, 2005	Kinoh et al.
	US 2005/0266566 A1	Dec. 1, 2005	Nagai et al.
	US 6,645,760 B2	Nov. 11, 2003	Nagai et al.
	US 6,723,532 B2	Apr. 20, 2004	Nagai et al.
	US 7,101,685 B2	Sep. 5, 2006	Nagai et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	EP 0 864 645 A1	Sep. 16, 1998	EPO	
	WO 95/16032 A1	Jun. 15, 1995	WIPO	
	WO 97/16539 A1	May 9, 1997	WIPO	Yes
	WO 00/70055 A1	Nov. 23, 2000	WIPO	Yes
	WO 00/70070 A1	Nov. 23, 2000	WIPO	Yes
	WO 03/025570 A1	Mar. 27, 2003	WIPO	Yes
	WO 03/029475 A1	Apr. 10, 2003	WIPO	Yes
	WO 03/072704 A2	Sep. 4, 2003	WIPO	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/062001
	Serial No.	10/598,947
	Applicant	Sueishi et al.
	Filing Date	September 15, 2006
	Group	1614
	IDS Filed	March 9, 2007

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO 03/093476 A1	Nov. 13, 2003	WIPO	Yes
	WO 03/102183 A1	Dec. 11, 2003	WIPO	Yes

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Behl et al., "Autoinduction of Platelet Derived Growth Factor (PDGF) A-Chain mRNA Expression in a Human Malignant Melanoma Cell Line and Growth Inhibitory Effects of PDGF-A-Chain mRNA-Specific Antisense Molecules," <i>Biochem. Biophys. Res. Commun.</i> 193(2): 744-751 (1993).
	Bergers et al., "Benefits of Targeting Both Pericytes and Endothelial Cells in the Tumor Vasculature with Kinase Inhibitors," <i>J. Clin. Invest.</i> 111(9): 1287-1295 (2003).
	Cao et al., "Angiogenesis Stimulated by PDGF-CC, a Novel Member in the PDGF Family, Involves Activation of PDGFR- α and - β Receptors," <i>FASEB J.</i> 16(12): 1575-1583 (2002).
	Compagni et al., "Fibroblast Growth Factors Are Required for Efficient Tumor Angiogenesis," <i>Cancer Res.</i> 60(24): 7163-7169 (2000).
	Dong et al., "VEGF-null Cells Require PDGFR α Signaling-Mediated Stromal Fibroblast Recruitment for Tumorigenesis," <i>EMBO J.</i> 23(14): 2800-2810 (2004).
	Eggert et al., "High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas," <i>Clin. Cancer Res.</i> 6(5): 1900-1908 (2000).
	Folkman, "Tumor Angiogenesis: Therapeutic Implications," <i>N. Engl. J. Med.</i> 285(21): 1182-1186 (1971).
	George, "Platelet-Derived Growth Factor Receptors: A Therapeutic Target in Solid Tumors," <i>Semin. Oncol.</i> 28(5 Suppl 17): 27-33 (2001).
	Goldman et al., "Paracrine Expression of a Native Soluble Vascular Endothelial Growth Factor Receptor Inhibits Tumor Growth, Metastasis, and Mortality Rate," <i>Proc. Nat. Acad. Sci. USA</i> 95(15): 8795-8800 (1998).
	Guba et al., "Rapamycin Inhibits Primary and Metastatic Tumor Growth by Antiangiogenesis: Involvement of Vascular Endothelial Growth Factor," <i>Nature Med.</i> 8(2): 128-135 (2002).
	Hlatky et al., "Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us," <i>J. Nat. Cancer Inst.</i> 94(12): 883-893 (2002).
	Holmgren et al., "Dormancy of Micrometastases: Balanced Proliferation and Apoptosis in the Presence of Angiogenesis Suppression," <i>Nature Med.</i> 1(2): 149-153 (1995).
	Jin et al., "Recombinant Sendai Virus Provides a Highly Efficient Gene Transfer into Human Cord Blood-Derived Hematopoietic Stem Cells," <i>Gene Ther.</i> 10(3): 272-277 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/062001
	Serial No.	10/598,947
	Applicant	Sueishi et al.
	Filing Date	September 15, 2006
	Group	1614
	IDS Filed	March 9, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Kuo et al., "Comparative Evaluation of the Antitumor Activity of Antiangiogenic Proteins Delivered by Gene Transfer," <i>Proc. Nat. Acad. Sci. USA</i> 98(8): 4605-4610 (2001).
	Masaki et al., "Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 but not of Fibroblast Growth Factor-2," <i>Circ. Res.</i> 90(9): 966-973 (2002).
	Nicosia et al., "Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Insulin-Like Growth Factor-1 Promote Rat Aortic Angiogenesis <i>In Vitro</i> ," <i>Am. J. Pathol.</i> 145(5): 1023-1029 (1994).
	Onimaru et al., "Fibroblast Growth Factor-2 Gene Transfer Can Stimulate Hepatocyte Growth Factor Expression Irrespective of Hypoxia-Mediated Downregulation in Ischemic Limbs," <i>Circ. Res.</i> 91(10): 923-930 (2002).
	Shikada et al., "A Role of Platelet-Derived Growth Factor -A (PDGF-A) in Non-Small Cell Lung Cancers and a Possibility of Platelet-Derived Growth Factor-A (PDGF-A) for Therapeutic Target Molecule," <i>J. Jpn. Surg. Soc.</i> 105: 284 (#SF-081-1) [Abstracts of the 104 th Annual Congress of Japan Surgical Society] (2004). (Translation attached).
	Shoji et al., "Airway-Directed Gene Transfer of Interleukin-10 Using Recombinant Sendai Virus Effectively Prevents Post-Transplant Fibrous Airway Obliteration in Mice," <i>Gene Ther.</i> 10(3): 213-218 (2003).
	Siegfried et al., "The Proteolytic Processing of Pro-Platelet-Derived Growth Factor-A at RRKR ⁶⁶ by Members of the Proprotein Convertase Family is Functionally Correlated to Platelet-Derived Growth Factor-A-Induced Functions and Tumorigenicity," <i>Cancer Res.</i> 63(7): 1458-1463 (2003).
	Takayama et al., "Suppression of Tumor Angiogenesis and Growth by Gene Transfer of a Soluble Form of Vascular Endothelial Growth Factor Receptor into a Remote Organ," <i>Cancer Res.</i> 60(8): 2169-2177 (2000).
	Tanaka et al., "Biologic Significance of Angiopoietin-2 Expression in Human Hepatocellular Carcinoma," <i>J. Clin. Invest.</i> 103(3): 341-345 (1999).
	Tiesman and Hart, "Identification of a Soluble Receptor for Platelet-Derived Growth Factor in Cell-Conditioned Medium and Human Plasma," <i>J. Biol. Chem.</i> 268(13): 9621-9628 (1993).
	Tsutsumi et al., "Essential Role of PDGFR α -p70S6K Signaling in Mesenchymal Cells During Therapeutic and Tumor Angiogenesis <i>In Vivo</i> : Role of PDGFR α During Angiogenesis," <i>Circ. Res.</i> 94(9): 1186-1194 (2004).
	Vincent and Rafii, "Vascular Frontiers Without Borders: Multifaceted Roles of Platelet-Derived Growth Factor (PDGF) in Supporting Postnatal Angiogenesis and Lymphangiogenesis," <i>Cancer Cell.</i> 6(4): 307-309 (2004).
	Yamashita et al., "Fibroblast Growth Factor-2 Determines Severity of Joint Disease in Adjuvant-Induced Arthritis in Rats," <i>J. Immunol.</i> 168(1): 450-457 (2002).
	International Search Report for PCT/JP2005/004485, mailed June 28, 2005.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	